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Abstract
To evaluate the impact of Birdshot-Retinochoroidopathy (BSRC) and Serpiginous Choroidi-
tis (SC) on depression, anxiety, and vision-related quality of life. 72 individuals (BSRC: n =
28, SC: n = 8; healthy control group (HC): n = 36) completed the Patient Health Question-
naire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and the Visual Function Ques-
tionnaire (VFQ-25). Multivariate linear regression models were used to analyze different
subscales of the PHQ-9, the GAD-7 and the VFQ-25. The results showed that the mean of
PHQ-9 was significantly higher while the mean of the VFQ-25 and its´ subscales were con-
sistently lower in the disease group compared to HC. The mean of GAD-7 was not signifi-
cantly lower in the disease group compared to HC. Stratification for different disease
severity stages and duration of disease did not reveal any differences in sum scores of
PHQ-9, GAD-7, and VFQ-25, whereas there were significant differences in some subscales
of the VFQ-25. We conclude that BSRC and SC patients show higher levels of depression
and a reduced visual quality of life due to imminent loss of vision. Because depression and
quality of life are adversely affected by lack of social contacts and functioning, psychological
treatment should enable patients to maintain their independence and ability to social interac-
tion. Psychosomatic care should be taken in account for the treatment of BSRC and SC.
Introduction
Birdshot-Retinochoroiditis (BSRC) and Serpiginous Choroiditis (SC) are rare forms of poste-
rior uveitis (1–3%), which cause severe, chronic, progressive inflammation of both eyes and
can lead to blurred vision and blindness [1, 2]. The prevalence of BSRC is higher in women,
while men have a greater prevalence of SC [2]. Both diseases affect people at working age, caus-
ing significant economic, social, and psychological burden [3, 4].
Although BSRC and SC affect only the eyes, systemic immunosuppressive therapy (IMT) is
required for these diseases, which can cause complications in other organ systems leading to a
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significant impact on quality of life [5]. Patients are exposed to blindness and adverse effects of
IMT, leading to psychological and social problems. In order to assess the psychosocial situa-
tion of the patient, questionnaires have been established to examine potential problems.
Assessment of health-related quality of life (HRQOL) is useful to examine physical and mental
health aspects of an affected individual [6–8]. In brief, quality of life includes social function-
ing, mental health, and physical health and there are only few studies that assessed visual qual-
ity of life in ophthalmologic patients [9–11].
Moreover, the chronic and progressive nature of posterior uveitis with risk of blindness
may place patients at greater risk for depression and anxiety. Only few studies have shown
patients with various ocular diseases, which were screened for depression and anxiety by use
of questionnaires [12–16]. Depression and anxiety have been determined as significant comor-
bidities among patients with severe ocular conditions such as glaucoma, age-related macular
degeneration, and retinitis pigmentosa [14–16]. But there have been only limited reports on
screening for psychological alterations in patients with uveitis [17–20].
We were particularly interested in BSRC and SC patients, who are at high risk of blindness
during the course of their disease due to atrophy of the retina and macula. Therefore, we
screened our patients with BSRC and SC for quality of life, depression, and anxiety and com-
pared the results with an age and gender matched healthy control group. We were interested
in: 1. the differences in the manifestation of symptoms of depression, anxiety, and of vision-
related quality of life between BSRC, SC, and HC, 2. the expression of depression, anxiety, and
vision-related quality of life depending on the duration and the severity of the disease, and 3.
the correlation of vision-related quality of life with depression as well as with anxiety.
Methods
Patient recruitment
This cross-sectional study enrolled patients with BSRC and SC who were scheduled for an
examination with multimodal imaging technique at Charité University of Medicine Berlin [21,
22]. Each patient was informed about the study and has given written consent. The patients
were asked to complete the PHQ-9, GAD-7, and VFQ-25. Further we recruited a healthy con-
trol group from a general public matched for age and gender. This study was approved by the
local ethics committee (EA4/055/16) of Charité Ethikkomission University of Medicine and
follows the declaration of Helsinki.
Questionnaires
We used the Patient Health Questionnaire (PHQ-9) to screen for symptoms of depression, the
Generalized Anxiety Disorder 7 (GAD-7) to screen for symptoms of anxiety, and the National
Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) to examine vision-related quality
of life.
PHQ-9. Symptoms of depression were assessed with the German version of the 9-item
Patient Health Questionnaire-Depression Scale (PHQ-9) [23]. Each item is scored from 0 to 3,
yielding a total score between 0 and 27. A total score�10 indicates the presence of a major
depressive disorder (MDD). Cronbach’s α in the present study sample was 0.805.
GAD-7. Symptoms of anxiety were assessed with the German version of the 7-item Gen-
eralized Anxiety Scale (GAD-7) [24]. The items are also scored from 0 to 3, yielding a total
score between 0 and 21. Cronbach’s α in the present study sample was 0.871. A cut-off of 8
implies the presence of generalized anxiety disorder, with a sensitivity of 92% and specificity of
76% for this diagnosis [25].
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VFQ-25. The VFQ-25 examines vision-related quality of life caused by visual impairments
or limitations. Emotional well-being and social functioning are captured by this questionnaire,
as well as task-oriented areas, for example the ability to cope with every day-life situation. The
questionnaire includes 25 items covering twelve subscales: “general vision”, “near and distance
vision activities”, “ocular pain”, “vision-related social function”, “vision-related role function”,
“vision-related mental health”, “vision-related dependency”, “driving difficulties”, “color
vision”, and “peripheral vision” [26]. The VFQ-25 also contains a general health item. The reli-
ability and validation of VFQ-25 has been proven to measure vision-targeted quality of life.
The German translation of VFQ-25 has been validated in two studies [10, 27]. The self-admin-
istered form of the VFQ-25 was chosen, so that the patient would not feel pressured by the
interviewer and would have sufficient time to complete the form. The evaluation of the VFQ-
25 follows an algorithm calculation with scores ranging from 0 to 100. The higher the score,
the better the functioning of vision and the higher quality of life. This study used the test man-
ual methodology to generate one total score by averaging the twelve subscale values [26].
Cronbach´s α for the VFQ-25 total score was 0.958 and ranged from 0.679 and 0.927 across
the twelve subscales.
Statistical analyses
All statistical tests were performed with SPSS version 24. For the first aim (differences in the
manifestation of depression, anxiety, and vision-related quality of life between BSRC, SC, and
HC) the two-sample t-test was used. The analysis of variance (ANOVA) and/or Kruskal-Wal-
lis-Test were used for the second aim (expression of depression, anxiety, and vision-related qual-
ity of life depending on the duration and severity of disease). For both tests a normal
distribution of the population and variance homogeneity were prerequisite. The normal distri-
bution was verified based on the Shapiro-Wilk test and variance homogeneity was verified
using the Levene-test. For the third aim (correlation of vision-related quality of life, depression
and anxiety) the Spearman- and Pearson-correlation was applied to correlate the subscales of
the VFQ-25 and the total scores of the PHQ-9 and GAD-7. In addition, a multiple linear
regression was utilized to analyze the impact of the different subscales of the VFQ-25 on
depression and anxiety. The level of significance was set at α = p<0.05.
Results
Subjects
In total, 72 subjects (disease group: n = 36 (BSRC: n = 28, SC: n = 8); HC: n = 36) were exam-
ined and included for statistical analyses. HC was matched for age and gender (Table 1).
Differences in the manifestation of depression, anxiety, and vision-related
quality of life between BSRC, SC, and HC
We hypothesized that differences can be found in the manifestation of depression, anxiety and
vision-related quality of life between the disease group and HC. Our data showed differences
in the manifestation of depression and vision-related quality of life between BSRC, SC and HC
(Figs 1 and 2). There were significant differences for PHQ-9 total score and for VFQ-25 total
score, as well as for all subscales of the VFQ-25 (Table 2), whereas no difference was found
regarding GAD-7. The mean of PHQ-9 total score was higher while the mean of the VFQ-25
total score and its subscales were consistently lower in the disease group compared to HC.
Thus, we confirmed our first hypothesis, showing higher levels of depression, but not anxiety,
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and lower levels for vision-related quality of life in the disease group compared to HC. There
was no significance between the two disease groups.
Expression of depression, anxiety, and vision-related quality of life
depending on the duration and severity of disease
Secondly, we hypothesized that the expression of depression, anxiety and vision-related quality
of life would deteriorate depending on the severity and disease duration in BSRC. The disease
severity levels of BSRC were graded from “active” to “inactive”, and then to “inactive burned-
out”. In the “active” group (n = 8), the mean age was 53.8 ± 10.5 years, and 62.5% were female.
The “inactive” group (n = 12) consisted of 33.33% females with a mean age of 61.1 ± 8.6 years.
The “inactive burned-out” group (n = 8) had 75% females and mean age was 68.5% ± 5.4
years. The SC group included only inactive disease, so that we focused on the BSRC group.
As for the severity of BSRC, no differences were found in the different subgroups of disease
severity stage regarding PHQ-9 (p = 0.931), GAD-7 (p = 0.665), and VFQ-25 (p = 0.055) using
Kruskal-Wallis-Test. To further specify this result, we considered the subscales of the VFQ-25
in our analysis. We could observe a decrease of the middle-ranking of the subscales of the
VFQ-25 in patients with “inactive burned-out” disease stage. Small values of middle ranking
indicate a low level of vision-related quality of life (Table 3).
Table 1. Demographic characteristics.
n (%) 76 (100)
Healthy group (n, %) 36 (50)
Disease group (n, %) 36 (50)
BSRC (n, %) 28 (78)
SC (n, %) 8 (22)
Mean age in years (+/- SD, range) 62 (+/-10; 38–84)
Visual acuity (logMAR)
BSRC (+/-SD, range) 0.4 (+/-0.6; 0–1.1)















Prednisolone <10mg 3 (8)
AD = Adalimumab; AZA = Azathioprine, BSRC = Birdshot Retinochoroiditis, CSA = Ciclosporine A;
logMAR = Logarithm of Minimum Angle of Resolution; MMF = Mycophenolate mofetil; MTX = Methotrexate;
IFN = Interferon; SC = Serpingiosa Choroiditis
https://doi.org/10.1371/journal.pone.0239210.t001
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Further, we analyzed PHQ-9, GAD-7 and VFQ-25 with respect to the disease duration. A
disease duration of 0 to 2 years occurred in 4 patients, of which 50% were female with a mean
age of 54.3 ± 14.3 years. Six patients had a disease duration of 3 to 4 years, of whom 50% were
female and had a similar mean age of 55.8 ± 12.6 years. A disease duration of 5 to 10 years
Fig 1. Differences in the manifestation of depression (PHQ-9 total score) in healthy control group and disease
group. � p<0.05.
https://doi.org/10.1371/journal.pone.0239210.g001
Fig 2. Differences in the manifestation of quality of life (VFQ-25 total score) in healthy control group and disease
group. ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0239210.g002
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occurred in 14 patients, of whom 50% were female with a mean age of 62.5 ± 5.4 years. Four
patients had a disease duration of 10 years or even more, of whom 75% were female with a
mean age of 71.0 ± 5.5 years. Based on the total score no differences were found in the different
disease groups according to the duration: PHQ-9 (p = 0.733), GAD-7 (p = 0.736), and VFQ-25
(p = 0.058) using Kruskal-Wallis-Test, unlike the subscales of the VFQ-25, where we calculated
significant differences according to disease duration (Table 4).
In sum, we could not confirm our second hypothesis. However, as for disease duration, sev-
eral aspects of vision-related quality of life seem to be impaired.
Table 2. Comparison of PHQ-9 and VFQ-25 scores between disease group and healthy controls using the Mann-Whitney-U-test.
Patients Healthy controls P value Cohen d
n mean n mean
PHQ-9 total score 36 42.08 36 30.92 0.023 0.554
GAD-7 total score 33 38.17 36 32.10 0.206
VFQ-25 general health item 35 29.37 36 42.44 0.003 0.668
VFQ-25 general visual acuity 35 27.53 36 44.24 <0.0001 0.885
VFQ-25 ocular pain 36 31.64 36 41.36 0.029 0.478
VFQ-25 near vision 36 24.89 36 48.11 <0.0001 1.334
VFQ-25 distance vision 36 23.76 36 49.24 <0.0001 1.534
VFQ-25 vision-related social function 36 28.32 36 44.68 <0.0001 0.851
VFQ-25 vision-related mental health 36 22.81 36 50.19 <0.0001 1.731
VFQ-25 vision-related role function 36 21.89 36 51.11 <0.0001 1.950
VFQ-25 vision-related dependency 36 27.00 36 46.00 <0.0001 1.019
VFQ-25 driving difficulties 32 21.16 30 42.53 <0.0001 1.768
VFQ-25 color vision 36 29.00 36 44.00 <0.0001 0.768
VFQ-25 peripheral vision 36 26.15 36 46.85 <0.0001 1.138
VFQ-25 total score 36 22.47 36 50.53 <0.0001 1.806
https://doi.org/10.1371/journal.pone.0239210.t002
Table 3. Results of the VFQ-25 subscales according to the Kruskal-Wallis-test, stratified by disease severity.
Scale Chi-squared P value Disease severity Middle- ranking Z value und P value (adjusted)
General visual acuity χ2 = 7.949 P = 0.015 Active 16.75 Z = 2.472 P = 0.040
Inactive 16.21 Z = 2.539 P = 0.033
Inactive „burned-out“ 7.07
Distance vision χ2 = 8.525 P = 0.010 Active 17.63 Z = 2.508 P = 0.026
Inactive 17.17 Z = 2.857 P = 0.026
Inactive „burned-out“ 7.38
Social functioning χ2 = 6.528 P = 0.032 Active 18.13 Z = 2.432 P = 0.045
Inactive „burned-out“ 8.94
Role difficulties χ2 = 7.423 P = 0.020 Inactive 17.46 Z = 2.573 P = 0.030
Inactive „burned-out“ 7.88
Dependence on others χ2 = 7.283 P = 0.023 Active 18.19 Z = 2.523 P = 0.035
Inactive „burned-out“ 8.38
Color vision χ2 = 7.625 P = 0.017 Active 17,38 Z = 2.419 P = 0.047
Inactive 16.54 Z = 2.439 P = 0.047
Inactive „burned-out“ 8.56
Peripheral vision χ2 = 7.754 P = 0.017 Active 18.13 Z = 2.548 P = 0.032
Inactive „burned-out“ 7.94
https://doi.org/10.1371/journal.pone.0239210.t003
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Correlation of vision-related quality of life, depression, and anxiety
In our third hypothesis, we postulated that VFQ-25 would correlate significantly with the total
scores of PHQ-9 and GAD-7. To verify this, we calculated the correlation coefficient according
to Spearmen. Our data showed significant correlations between the subscales of VFQ-25 and
PHQ-9 (Table 5), but not with GAD-7. To specify the relationship between vision-related
quality of life and depression, we performed a multiple linear regression analysis including all
subscales of VFQ-25. The model was significant (F(12,18) = 4.15, P = 0.003, R2 = 0.735, R2corr
= 0.558). This means that 55.8% of the variance of vision-related quality of life can be explained
by depression. According to this result, subscales of the VFQ-25 can be used as a good predic-
tor for the expression of depression [28]. In the second step of our linear regression model, the
VFQ-25 subscale “mental health” was found to be significant (p = 0.001) (Table 6).
Discussion
This study revealed the effects of impending or vision loss on depression, anxiety, and vision-
related quality of life in vision threatening diseases. We found that BSRC and SC patients had
higher levels of depression, and lower levels of vision-related quality of life, compared to HC.
Duration of disease impaired several aspects of vision-related quality of life. The VFQ-25 sub-
scale “mental health” positively predicted the occurrence of symptoms of depression in BSRC
and SC patients compared to HC.
Patients with chronic somatic diseases have a high risk to display depression and anxiety
[29]. In comparison to chronic somatic conditions, patients with reduced visual acuity even
show higher levels of symptoms of depression and anxiety [30]. It is assumed that the deterio-
ration of visual acuity, rather than the chronicity of the disease, leads to the manifestation of
depression and anxiety in older people [30]. Since, in our study, the healthy control group was
Table 4. Results of the VFQ-25 subscales according to the Kruskal-Wallis-test, stratified by disease duration.
Scale Chi-squared P value Disease duration Middle- ranking Z value und P value (adjusted)
Near vision χ2 = 8.816 P = 0.021 0–2 years 21.00 Z = 2.857 P = 0.026
> 10 years 4.50
Distance vision χ2 = 8.816 P = 0.021 0–2 years 19.88 Z = 2.857 P = 0.026
> 10 years 4.63
Social functioning χ2 = 8,816 P = 0.021 0–2 years 21.00 Z = 2.857 P = 0.026
> 10 years 5.50
Role difficulties χ2 = 8.816 P = 0.021 3–4 years 19.33 Z = 2.857 P = 0.026
> 10 years 3.88
Dependence on others χ2 = 8,816 P = 0.021 0–2 years 22.00 Z = 2.857 P = 0.026
> 10 years 5.63
https://doi.org/10.1371/journal.pone.0239210.t004
Table 5. Correlation coefficients, P values, and confidence measures for the relationship between the subscales
scores of the VFQ-25 and the PHQ-9.
Scale rs P n r2
Distance vision -0.357 0.032 36 0.127
Role difficulties -0.345 0.039 36 0.119
Driving difficulties -0.371 0.036 32 0.138
Mental health -0.521 0.001 36 0.271
Dependence on others -0.427 0.009 36 0.182
Peripheral vision -0.461 0.005 36 0.213
https://doi.org/10.1371/journal.pone.0239210.t005
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matched for age and gender, the impact of these parameters may be less likely to account for
the differences in our study. In line with our findings, Augustin et al. did not find evidence for
anxiety disorder in patients with age-related macular degeneration [31]. Moreover, Onal et al.
found that 52.5% patients with uveitis screened for symptoms of anxiety were younger (Mean
age: 31.5 vs. 40 years, p = 0.009) and had earlier onset of uveitis (Mean age: 26 vs. 35 years,
p = 0.015) [17]. Since the mean age of the patients in this study was approximately 62 years,
age might contribute to the missing significance of symptoms of anxiety in the disease group.
We found no significant differences in the expression of depression, anxiety, and vision-
related quality of life in groups with various disease severity or disease duration, concordant to
the work of Kuiper et al [32]. However, we found differences in the subscales of VFQ-25, that
are relevant to everyday life. Both, BSRC and SC, are progressive conditions, with widely
uncontrolled inflammation of the retina and the choroid, which leads to degeneration of pho-
toreceptor layers and ultimately to blindness [21, 33]. While active inflammation with vasculi-
tis and choroiditis usually occurs unnoticed, unless patients suffer from severe vitreous haze
and macular edema, the “inactive burned-out” disease is more problematic due to retinal
hypoperfusion and atrophy [21], which is reflected in our results. The “inactive burned-out”
group showed decreased subscales of VFQ-25 in distance, peripheral, and color vision. In
addition, the duration of inflammation is a risk factor for retinal and macular thinning with
ellipsoid zone disruption [21], which is also reflected by our results. We observed significant
differences of VFQ-25 subscales between a short disease duration (0–2 years) and a long dis-
ease duration (> 10 years). Comparable results were published, where patients experienced
color blindness and limited peripheral vision at later stages of disease [34]. Both groups,
respectively, showed differences in “role difficulties”, “social functioning”, and “dependence
on others”. The vision-related quality of life in relation to these subscales was strongly related
to the patient´s ability to cope with daily life. In line with this, Kempen et al. showed that
impaired vision was associated with impairment in the ability to handle daily life activities
[30]. Moreover, our results show that the progressive visual limitations do not limit activities
of daily life at once, but rather were associated with a continuing decline. We conclude this
from the fact that the middle-ranking of the subscales decrease continuously, rather than
reaching a constant level after a short period of time, i.e. disease duration. Long-term studies
would be needed, in order to verify our finding. Additionally, the subscale “dependence on
Table 6. Multiple linear regression analysis for the prediction of VFQ-25 subscales for symptoms of depression.
VFQ-25 subscales Regression coefficient β T P
Constant 15.163 4.368 <0.0001
General health 0.052 1.304 0.209
General visual acuity 0.026 0.543 0.594
Eye pain -0.018 -0.548 0.591
Near vision 0.019 0.200 0.843
Distance vision -0.012 -0.185 0.855
Social functioning 0.049 1.036 0.314
Mental health -0.184 -3.772 0.001
Role difficulties 0.013 0.381 0.708
Dependence on others -0.091 -1.645 0.117
Driving difficulties -0.010 -0.424 0.677
Color vision 0.066 2.073 0.053
Peripheral vision -0.034 -1.086 0.292
https://doi.org/10.1371/journal.pone.0239210.t006
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others” should be considered in more detail in the future. Kempen et al. found that older per-
sons (Mean: age: 77.4) with vision loss reported higher level of social support [30].
We demonstrated that subscales of the VFQ-25 predict the expression of symptoms of
depression, especially the subscale “mental health”. This is somewhat trivial, since PHQ-9 rec-
ords the expression of symptoms of depression, which in turn is a mental illness that negatively
affects mental health. Therefore, it is self-explanatory that a total score that measures depres-
sion, as a mental limitation, correlates with the VFQ-25 subscale “mental health”. In addition,
the VFQ-25 subscale “mental health” also captures the feeling of loss of control [35]. Lack of
control over the feeling of worry is a sign of generalized anxiety disorder [36]. However, a sig-
nificantly higher severity of generalized anxiety disorder in the disease group could not be
observed. But we were able to show in our study that vision-related quality of life is related to
“social functioning”, “role difficulties”, and “dependence on others”. It can be concluded that
depression and quality of life are adversely affected by lack of social contacts and lack of social
functioning. Thus, the focus of a treatment in BSRC and SC patients should be on maintaining
the independence and ability for social interaction. Patients would benefit from psychological
interventions that would support them to maintain their independence and help them to par-
ticipate in public life and solve tasks of daily life, despite their visual impairment. Confidence
in one´s own abilities should be maintained or restored.
The study has a few limitations. The sample size is small and makes it difficult to generalize
the results. A multicenter study should be conducted to overcome the low incidence and prev-
alence of the diseases. Some of the items of the questionnaires were not completed, and we did
not check for completeness.
In conclusion, our results demonstrated that BSRC and SC patients have a higher manifes-
tation of depression and a reduced vision-related quality of life due to imminent loss of vision.
No difference in the levels of depression, anxiety, and vision-related quality of life for the vari-
ous disease severity and disease durations of BSRC could be recorded, but for some subscales
of vision-related quality of life. “Mental health”, which is a predictor of depression should not
be underestimated in the disease group. Therefore, a mental health worker specialized in psy-
chosomatic care, should be involved. Early diagnosis of mental health disorders can improve
the progression and prognosis of depression in BSRC and SC patients.
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Data curation: Dominika Pohlmann, Anne Barth, Sergio Macedo.
Formal analysis: Anne Barth.
Investigation: Anne Barth.
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PLOS ONE Depression, anxiety, and vision-related quality of life in Choroiditis
PLOS ONE | https://doi.org/10.1371/journal.pone.0239210 October 5, 2020 9 / 11
Visualization: Dominika Pohlmann, Uwe Pleyer, Sibylle Winterhalter, Özgür Albayrak.
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